摘要:[I]n the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new strategy required medicinal chemists to design drug candidates with structural features that optimized pharmacological (e.g., high affinity and specificity for the target receptor), pharmaceutical (e.g., solubility and chemical stability), biopharmaceutical (e.g., cell membrane permeability), and metabolic/pharmacokinetic (e.g., metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, including scientists from drug design (e.g., medicinal chemists, cell biologists, enzymologists, pharmacologists) and drug development (e.g., analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). , With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the scientific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug discovery."--Page viii.
